Cargando…
Evolution of Dihydropyrimidine Dehydrogenase Diagnostic Testing in a Single Center during an 8-Year Period of Time
OBJECTIVE: Fluoropyrimidine treatment can be optimized based on dihydropyrimidine dehydrogenase (DPD) activity. DPD dysfunction leads to increased exposure to active metabolites, which can result in severe or even fatal toxicity. METHODS: We provide an overview of 8 years of DPD diagnostic testing (...
Autores principales: | Coenen, Marieke J.H., Paulussen, Aimée D.C., Breuer, Marc, Lindhout, Martijn, Tserpelis, Demis C.J., Steyls, Anja, Bierau, Jörgen, van den Bosch, Bianca J.C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6258870/ https://www.ncbi.nlm.nih.gov/pubmed/30510603 http://dx.doi.org/10.1016/j.curtheres.2018.10.001 |
Ejemplares similares
-
Potential added value of combined DPYD/DPD genotyping and phenotyping to prevent severe toxicity in patients with a DPYD variant and decreased dihydropyrimidine dehydrogenase enzyme activity
por: Ockeloen, Charlotte W, et al.
Publicado: (2021) -
Erythrocyte Inosine Triphosphatase Activity Is Decreased in HIV-Seropositive Individuals
por: Bierau, Jörgen, et al.
Publicado: (2012) -
Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe
por: de With, M., et al.
Publicado: (2023) -
Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer.
por: Ridge, S. A., et al.
Publicado: (1998) -
Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity
por: Milano, G, et al.
Publicado: (1999)